Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors
Open accessAbstract
In addition to their therapeutic effect, all drugs have unwanted effects. For the purpose of this MiniReview, unwanted drug effects will be discussed as either predictable, dose-dependent effects, or as less predictable events which only occur in patients pre-disposed to unwanted drug reactions when confronted with specific situations. While clinicians have long been using biomarkers to identify patients prone to less predictable unwanted drug effects, emerging data clearly suggest that such effects are often a consequence of interactions between drug effects, drug metabolism, an individual, at times genetically conferred pre-disposition to the interaction, and transient pre-disposing factors. This paper describes general principles of predictable and less predictable unwanted drug effects and discusses the complex interplay of genetic and acquired pre-disposing and precipitating factors for such effects using the example of ventricular pro-dysrhythmia. The latter, an important unwanted effect of many drugs, is a common yet not fully understood less predictable cardiac drug effect. Understanding the mechanisms of ventricular pro-dysrhythmia may allow to predict this unwanted drug effect better, and to identify novel markers for such events in the future.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Monitoring PR, QT, and QRS durations during initiation of antiarrhythmic drug therapy can identify patients at higher risk of drug-induced proarrhythmia on longer-term treatment.
“monitoring PR, QT, and QRS durations during initiation of antiarrhythmic drug therapy can identify patients at higher risk of drug-induced proarrhythmia on longer-term treatment.[669][670][671]”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [670]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo
Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241201 · Cited by 3,244 · see citing works
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805 · see citing works
Systematic overview of warfarin and its drug and food interactions
Holbrook, A. M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1095 · Cited by 1,160 · see citing works
Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
Hohnloser, S. H., Crijns, H. J. G. M., van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C. T., & Connolly, S. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803778 · Cited by 1,125 · see citing works
Gage, B. F., Yan, Y., Milligan, P. E., Waterman, A. D., Culverhouse, R., Rich, M. W., & Radford, M. J. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.017 · Cited by 1,008 · see citing works
Drug induced QT prolongation and torsades de pointes
Yap, Y. G., & Camm, A. J. (2003) · Heart · doi:10.1136/heart.89.11.1363 · Cited by 958 · see citing works
The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis
Jackman, W. M., Friday, K. J., Anderson, J. L., Aliot, E. M., Clark, M., & Lazzara, R. (1988) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(88)90014-x · Cited by 783 · see citing works
Long QT syndromes and torsade de pointes
Viskin, S. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02107-8 · Cited by 690 · see citing works
Authors Task Force Members, Fuster, V., Rydén, L., Cannom, D. S., Crijns, H. J. G. M., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Heuzey, J. L., Kay, G. N., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl176 · Cited by 645 · see citing works
Genetic Determinants of Response to Warfarin during Initial Anticoagulation
Schwarz, U. I., Ritchie, M. D., Bradford, Y., Li, C., DUDEK, S. M., Frye-Anderson, A., Kim, R. B., Roden, D. M., & Stein, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708078 · Cited by 572 · see citing works
Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes
Ray, W. A., Murray, K. T., Meredith, S., Narasimhulu, S. S., Hall, K., & Stein, C. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040582 · Cited by 493 · see citing works
Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death
Haddad, P. M., & Anderson, I. M. (2002) · Drugs · doi:10.2165/00003495-200262110-00006 · Cited by 436 · see citing works
[Ventricular tachycardia with 2 variable opposing foci].
Dessertenne, F. (1966) · PubMed · Cited by 414 · see citing works
Haverkamp, W. (2000) · European Heart Journal · doi:10.1053/euhj.2000.2249 · Cited by 414 · see citing works
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial
FETSCH, T. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.04.015 · Cited by 334 · see citing works
The ESC Textbook of Cardiovascular Medicine
(2009) · doi:10.1093/med/9780199566990.001.0001 · Cited by 325 · see citing works
Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation
Lafuente‐Lafuente, C., Mouly, S. J., Longás-Tejero, M. A., Mahé, I., & Bergmann, J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.719 · Cited by 283 · see citing works
Healey, J. S., Hart, R. G., Pogue, J. M., Pfeffer, M. A., Hohnloser, S. H., Caterina, R. D., Flaker, G., Yusuf, S., & Connolly, S. J. (2008) · Stroke · doi:10.1161/strokeaha.107.500199 · Cited by 225 · see citing works
Psychotropic Drugs, Cardiac Arrhythmia, and Sudden Death
Witchel, H. J., Hancox, J. C., & Nutt, D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00010 · Cited by 219 · see citing works
Kirchhof, P., Bax, J., Blomstrom-Lundquist, C., Calkins, H., Camm, A. J., Cappato, R., Cosio, F., Crijns, H., Diener, H.-C., Goette, A., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp235 · Cited by 202 · see citing works
Self-citationMorganroth, J., Anderson, J. L., & Gentzkow, G. D. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80190-5 · Cited by 153 · see citing works
Experimental models of torsade de pointes
Eckardt, L. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00043-1 · Cited by 145 · see citing works
Wang, Y., Zhang, W., Zhang, Y., Yang, Y., Sun, L., Hu, S., Chen, J., Zhang, C., Zheng, Y. Z., Zhen, Y., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.580167 · Cited by 144 · see citing works
Giant T–U Waves Precede Torsades de Pointes in Long QT Syndrome
Kirchhof, P., Franz, M. R., Bardai, A., & Wilde, A. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.043 · Cited by 112 · see citing works
KAAB, S. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00806-0 · Cited by 111 · see citing works
Honig, P. K., Wortham, D. C., Hull, R. W., Zamani, K., Smith, J. E., & Cantilena, L. R. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03920.x · Cited by 104 · see citing works
Clinical Observations With the Amiodarone/Warfarin Interaction
Sanoski, C. A., & Bauman, J. L. (2002) · CHEST Journal · doi:10.1378/chest.121.1.19 · Cited by 103 · see citing works
Greenberg, H., Dwyer, E. M., Hochman, J. S., Steinberg, J. S., Echt, D. S., & Peters, R. W. (1995) · Heart · doi:10.1136/hrt.74.6.631 · Cited by 100 · see citing works
Coromilas, J., Saltman, A. E., Waldecker, B., et al. (1995) · Circulation · doi:10.1161/01.cir.91.8.2245 · Cited by 89 · see citing works
Lehtonen, A., Fodstad, H., Laitinen-Forsblom, P. J., Toivonen, L. K., KONTULA, K. K., & Swan, H. (2007) · Heart Rhythm · doi:10.1016/j.hrthm.2007.01.019 · Cited by 89 · see citing works
Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone
Anderson, J. L., Askins, J. C., Gilbert, E. M., Menlove, R. L., & Lutz, J. R. (1986) · American Heart Journal · doi:10.1016/0002-8703(86)90050-5 · Cited by 80 · see citing works
Is QT interval prolongation harmful? A regulatory perspective
Botstein, P. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90041-a · Cited by 62 · see citing works
Primary prevention of sudden cardiac death
Kirchhof, P. F., Breithardt, G., & Eckardt, L. (2006) · Heart · doi:10.1136/hrt.2006.087957 · Cited by 42 · see citing works
Self-citationTorsade de pointes induced by terfenadine in a patient with long QT syndrome
Koh, K. K., Rim, M. S., Yoon, J., & Kim, S. S. (1994) · Journal of Electrocardiology · doi:10.1016/s0022-0736(05)80274-2 · Cited by 41 · see citing works
Kirchhof, P. F., Fetsch, T., Hanrath, P., Meinertz, T., Steinbeck, G., Lehmacher, W., & BREITHARDT, G. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.07.020 · Cited by 36 · see citing works
Self-citation[The long QT syndrome and syncope caused by spike torsades].
Motté, G., Coumel, P., Abitbol, G., et al. (1970) · PubMed · Cited by 35 · see citing works
Pharmacogenetics of antiarrhythmic therapy
Darbar, D., & Roden, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.12.1583 · Cited by 33 · see citing works
Terfenadine Alters Action Potentials in Isolated Canine Purkinje Fibers More Than Acrivastine
Lang, D. G., Wang, C. M., & Wenger, T. L. (1993) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199309000-00014 · Cited by 22 · see citing works
Recognition of unwanted drug effects.
Doll, R. (1969) · BMJ · doi:10.1136/bmj.2.5649.69 · Cited by 20 · see citing works
Preclinical Testing of Drug-Induced Proarrhythmia: Value of Transgenic Models
Fabritz, L., BREITHARDT, G. E., & Kirchhof, P. F. (2007) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152507782109881 · Cited by 4 · see citing works
Self-citationA symposium: Perspectives on proarrhythmia. March 9, 1986, Atlanta, Georgia. Proceedings.
(1987) · PubMed · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- Haverkamp W, Haverkamp F, Breithardt G. Drug-induced QT prolongation and torsade de pointes -an interdisciplinary prob- lem (Medikamentenbedingte QT-Verlängerung und Torsade de pointes). Dtsch ¾rztebl 2003;99:A1972-9.
- Bazett HC. An analysis of the time-relations of the electrocardio- gram. Heart 1920;7:353-70.
- Darbar D, Roden DM. Pharmacogenetics of antiarrhythmic ther- apy. Expert Opin Pharmacother 2006;7:1583-90.
- Camm AJ, Kirchhof P, Lip G, Savelieva I, Ernst S. Atrial fibrilla- tion. In: Camm AJ, Serruys PW, Luscher T (eds). The ESC Text- book of Cardiology, Chapter 29, Vol 1, 2nd edn. Oxford University Press, Oxford, 2009;1069-1131.
Cited by
Sorted by citations
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418 · see citing works
Self-citation2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955 · see citing works
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403 · see citing works
Self-citationKirchhof, P., Breithardt, G., Aliot, E., Al Khatib, S., Apostolakis, S., Auricchio, A., Bailleul, C., Bax, J., Benninger, G., Blomstrom-Lundqvist, C., et al. (2013) · Europace · doi:10.1093/europace/eut232 · Cited by 141 · see citing works
- Authors
- Fabritz, L., & Kirchhof, P.
- Affiliations
- University Hospital Münster (DE)
- Corresponding author
- Fabritz, Larissa
- Venue
- Basic & Clinical Pharmacology & Toxicology
- Publisher
- Wiley
- Published
- 2010-02-11
- Volume
- 106
- Issue
- 3
- Pages
- 263-268
- ISSN
- 1742-7835 (ISSN-L)
- 1742-7843
- OpenAlex
- W2136363237
- Cited by
- 28
- References
- 41
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 1 · 2017: 1 · 2016: 4 · 2015: 3 · 2014: 5 · 2013: 4
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Basic & Clinical Pharmacology & Toxicology (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Fondation Leducq
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- adverse drug reactions, drug-induced arrhythmia, genetic susceptibility, biomarkers, drug metabolism, drug-drug interactions, dose-dependent effects, cardiovascular drugs
- MeSH terms
- Animals, Arrhythmias, Cardiac, Cardiovascular Agents, Dose-Response Relationship, Drug, Electrocardiography, Humans, Long QT Syndrome, Prognosis, Risk Factors, Precipitating Factors, Torsades de Pointes, Sodium Channel Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
